Edition:
United States

Novocure Ltd (NVCR.OQ)

NVCR.OQ on NASDAQ Stock Exchange Global Select Market

20.60USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$20.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
211,716
52-wk High
$24.12
52-wk Low
$6.75

Latest Key Developments (Source: Significant Developments)

Novocure Ltd Reports Qtrly Net Loss Per Ordinary Share Of $0.12
Thursday, 22 Feb 2018 06:00am EST 

Feb 22 (Reuters) - Novocure Ltd ::QTRLY NET REVENUES $53.7 MILLION VERSUS $30.2 MILLION.QTRLY NET LOSS PER ORDINARY SHARE $0.12.Q4 EARNINGS PER SHARE VIEW $-0.11, REVENUE VIEW $53.5 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Novocure Secures New $150 Mln Non-Dilutive Term Loan Financing
Wednesday, 7 Feb 2018 04:01pm EST 

Feb 7 (Reuters) - Novocure Ltd ::NOVOCURE SECURES NEW $150 MILLION NON-DILUTIVE TERM LOAN FINANCING.NOVOCURE LTD - ‍PROCEEDS OF TERM LOAN FINANCING USED TO PAY IN FULL NOVOCURE'S EXISTING $100 MILLION TERM LOAN DEBT AND FUND WORKING CAPITAL ​.NOVOCURE LTD - ‍AGREEMENT IMPROVES PRICING AND TERMS OF CO'S EXISTING CREDIT FACILITY & EXTENDS MATURITY OF CO'S DEBT UNTIL FEB 2023​.  Full Article

Minerva Neurosciences Names Remy Luthringer As Executive Chairman
Monday, 5 Feb 2018 08:30am EST 

Feb 5 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR.SAYS CHAIRMAN OF THE BOARD MARC BEER RESIGNED.MINERVA NEUROSCIENCES - WILLIAM DOYLE IS EXECUTIVE CHAIRMAN OF NOVOCURE.  Full Article

Novocure Receives FDA IDE Approval For Its PANOVA 3 Phase 3 Pivotal Clinical Trial In Advanced Pancreatic Cancer
Monday, 18 Dec 2017 07:37am EST 

Dec 18 (Reuters) - Novocure Ltd ::NOVOCURE RECEIVES FDA IDE APPROVAL FOR ITS PANOVA 3 PHASE 3 PIVOTAL CLINICAL TRIAL IN ADVANCED PANCREATIC CANCER.NOVOCURE LTD - RECEIVED A U.S. FOOD AND DRUG ADMINISTRATION INVESTIGATIONAL DEVICE EXEMPTION APPROVAL TO INITIATE ITS PANOVA 3 CLINICAL TRIAL.  Full Article

Novocure Receives Reimbursement Approval For Optune In Japan For Treatment Of Glioblastoma
Friday, 1 Dec 2017 07:30am EST 

Dec 1 (Reuters) - Novocure Ltd ::NOVOCURE RECEIVES REIMBURSEMENT APPROVAL FOR OPTUNE® IN JAPAN FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA.NOVOCURE-‍JAPANESE MINISTRY OF HEALTH, LABOUR & WELFARE APPROVED RECOMMENDATION TO PROVIDE REIMBURSEMENT FOR OPTUNE TO TREAT NEWLY DIAGNOSED GLIOBLASTOMA​.  Full Article

Novocure reports qtrly ‍loss per share $0.13​
Thursday, 26 Oct 2017 06:00am EDT 

Oct 26 (Reuters) - Novocure Ltd :Novocure Ltd - Qtrly ‍loss per share $0.13​.Novocure Ltd - ‍Q3 2017 net revenues of $50.1 million, reflecting 131 percent growth versus Q3 2016​.  Full Article

Novocure says German Federal Joint Committee supports Optune trial
Tuesday, 5 Sep 2017 07:41am EDT 

Sept 5 (Reuters) - Novocure Ltd ::German Federal Joint Committee published decision to support clinical trial studying optune for treatment of newly diagnosed glioblastoma​.Novocure and G-BA will share costs for conduct of clinical trial.German Ministry of Health approval process, subsequent initiation of clinical trial anticipated to take up to additional 18 months, longer.Co ‍will continue to bill German healthcare payers for individual cases till the German Ministry of Health approval process​ takes place.  Full Article

Novocure qtrly net revenues $38.4 mln
Thursday, 27 Jul 2017 06:00am EDT 

July 27 (Reuters) - Novocure Ltd ::Novocure Ltd - ‍for three months ended June 30, 2017, net revenues increased to $38.4 million compared to $17.9 million for same period in 2016​.Novocure Ltd - qtrly basic and diluted net loss per ordinary share $0.24.Q2 earnings per share view $-0.22, revenue view $40.4 million -- Thomson Reuters I/B/E/S.  Full Article

Pomona Capital VII reports 11.3 pct passive stake in Novocure
Thursday, 23 Mar 2017 05:40pm EDT 

Novocure Ltd - :Pomona Capital VII Lp reports 11.3 percent passive stake in Novocure Ltd as of March 8 - SEC filing.  Full Article

Novocure receives MHLW approval for second generation optune in Japan
Monday, 20 Mar 2017 07:00am EDT 

Novocure Ltd : Novocure Ltd - Novocure receives MHLW approval for second generation optune in Japan .Novocure Ltd - announced that Japanese Ministry Of Health, Labour And Welfare (MHLW) has approved second generation optune.  Full Article

BRIEF-Novocure Ltd Reports Qtrly Net Loss Per Ordinary Share Of $0.12

* Q4 EARNINGS PER SHARE VIEW $-0.11, REVENUE VIEW $53.5 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage: